ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
ImmuCell (Nasdaq: ICCC) will announce its unaudited financial results for the quarter ended June 30, 2024, after market close on Tuesday, August 13, 2024. A conference call is scheduled for Wednesday, August 14, 2024, at 9:00 AM ET to review these results. Access the call at (844) 855-9502 (toll-free) or (412) 317-5499 (international). A replay is available until August 21, 2024, at (877) 344-7529 (toll-free) or (412) 317-0088 (international), using access code #3744296.
The Company expects no changes to the preliminary sales results disclosed on July 9, 2024. The Quarterly Report on Form 10-Q will be filed after market close on August 13, 2024. Investors are encouraged to review the updated Corporate Presentation slide deck on the Company's website post-announcement.
ImmuCell (Nasdaq: ICCC) annuncerà i suoi risultati finanziari non auditati per il trimestre conclusosi il 30 giugno 2024, dopo la chiusura del mercato di martedì 13 agosto 2024. È previsto un call conference per mercoledì 14 agosto 2024, alle 9:00 AM ET per esaminare questi risultati. È possibile partecipare alla chiamata al (844) 855-9502 (numero verde) o al (412) 317-5499 (internazionale). Una registrazione sarà disponibile fino al 21 agosto 2024, al (877) 344-7529 (numero verde) o al (412) 317-0088 (internazionale), utilizzando il codice di accesso #3744296.
La Società non prevede cambiamenti ai risultati preliminari delle vendite comunicati il 9 luglio 2024. Il Rapporto Trimestrale sul Modulo 10-Q sarà presentato dopo la chiusura del mercato il 13 agosto 2024. Gli investitori sono invitati a rivedere la presentazione aziendale aggiornata sul sito web della Società dopo l'annuncio.
ImmuCell (Nasdaq: ICCC) anunciará sus resultados financieros no auditados para el trimestre que terminó el 30 de junio de 2024, después del cierre del mercado el martes 13 de agosto de 2024. Se programó una llamada de conferencia para el miércoles 14 de agosto de 2024, a las 9:00 AM ET para revisar estos resultados. Acceda a la llamada al (844) 855-9502 (número gratuito) o al (412) 317-5499 (internacional). Una repetición estará disponible hasta el 21 de agosto de 2024, al (877) 344-7529 (número gratuito) o al (412) 317-0088 (internacional), utilizando el código de acceso #3744296.
La Compañía no espera cambios en los resultados preliminares de ventas divulgados el 9 de julio de 2024. El Informe Trimestral en el Formulario 10-Q se presentará después del cierre del mercado el 13 de agosto de 2024. Se alienta a los inversores a revisar la presentación corporativa actualizada en el sitio web de la Compañía después del anuncio.
ImmuCell (Nasdaq: ICCC)는 2024년 6월 30일 종료된 분기의 비회계 감사 재무 결과를 2024년 8월 13일 화요일 시장 종료 후 발표합니다. 이 결과를 검토하기 위해 2024년 8월 14일 수요일 오전 9:00 (동부 표준시)에 컨퍼런스 콜이 예정되어 있습니다. 참가할 수 있는 전화번호는 (844) 855-9502 (무료전화) 또는 (412) 317-5499 (국제전화)입니다. 재생은 (877) 344-7529 (무료전화) 또는 (412) 317-0088 (국제전화)로 2024년 8월 21일까지 가능합니다. 엑세스 코드는 #3744296입니다.
회사는 2024년 7월 9일 발표된 판매의 예비 결과에 변경이 없을 것으로 예상하고 있습니다. 10-Q 양식의 분기 보고서는 2024년 8월 13일 시장 종료 후 제출될 예정입니다. 투자자들은 발표 이후 회사 웹사이트에서 업데이트된 기업 프레젠테이션 슬라이드 자료를 검토할 것을 권장합니다.
ImmuCell (Nasdaq: ICCC) annoncera ses résultats financiers non audités pour le trimestre clos le 30 juin 2024, après la clôture des marchés le mardi 13 août 2024. Une conférence téléphonique est prévue pour le mercredi 14 août 2024, à 9h00 ET afin de passer en revue ces résultats. Accédez à l'appel au (844) 855-9502 (numéro vert) ou au (412) 317-5499 (international). Un enregistrement sera disponible jusqu'au 21 août 2024, au (877) 344-7529 (numéro vert) ou au (412) 317-0088 (international), en utilisant le code d'accès #3744296.
La Société n'anticipe aucun changement dans les résultats préliminaires des ventes divulgués le 9 juillet 2024. Le Rapport trimestriel sur le formulaire 10-Q sera déposé après la clôture des marchés le 13 août 2024. Les investisseurs sont encouragés à consulter la présentation d'entreprise mise à jour sur le site web de la Société après l'annonce.
ImmuCell (Nasdaq: ICCC) wird seine unauditierten Finanzzahlen für das am 30. Juni 2024 endende Quartal nach Marktschluss am Dienstag, den 13. August 2024 bekannt geben. Eine Telefonkonferenz ist für Mittwoch, den 14. August 2024, um 9:00 Uhr ET geplant, um diese Ergebnisse zu besprechen. Sie können an der Konferenz unter (844) 855-9502 (gebührenfrei) oder (412) 317-5499 (international) teilnehmen. Eine Wiederholung ist bis zum 21. August 2024 unter (877) 344-7529 (gebührenfrei) oder (412) 317-0088 (international) verfügbar, mit dem Zugangscode #3744296.
Das Unternehmen erwartet keine Änderungen bei den vorläufigen Verkaufszahlen, die am 9. Juli 2024 veröffentlicht wurden. Der Quartalsbericht auf Formular 10-Q wird nach Marktschluss am 13. August 2024 eingereicht. Investoren werden ermutigt, die aktualisierte Unternehmenspräsentation auf der Website des Unternehmens nach der Ankündigung zu überprüfen.
- ImmuCell will announce unaudited financial results promptly after market close on August 13, 2024.
- Timely scheduled conference call to review financial results the next morning, demonstrating transparency.
- Company anticipates no changes to preliminary sales results.
- None.
Conference Call Scheduled for Wednesday, August 14, 2024 at 9:00 AM ET
PORTLAND, Maine, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2024 after the market closes on Tuesday, August 13, 2024.
The Company is planning to host a conference call the next morning, Wednesday, August 14, 2024, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until August 21, 2024 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #3744296.
The Company anticipates no change to the preliminary sales results for the second quarter ended June 30, 2024 that were disclosed on July 9, 2024. The Company expects to file its Quarterly Report on Form 10-Q after the market closes on August 13, 2024.
Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company. An updated version of the slide deck will be made available under the “Investors” tab of the Company’s website after the market closes on August 13, 2024.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or meat withhold claims that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Michael F. Brigham, President and CEO ImmuCell Corporation (207) 878-2770 | |
| Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 iccc@lythampartners.com | ||
FAQ
When will ImmuCell announce its unaudited financial results for Q2 2024?
What is the ticker symbol for ImmuCell ?
When is the conference call to review ImmuCell's Q2 2024 financial results?
How can I access the conference call for ImmuCell's Q2 2024 financial results?
Will there be a replay available for ImmuCell's Q2 2024 financial results conference call?
Where can investors find ImmuCell's updated Corporate Presentation slide deck?
